Cover Page

Cite item


Background: Despite the number of publications related to the expression of surface antigens of periphery blood lymphocytes in chronic obstructive pulmonary disease (COPD), algorithm for interpreting of the results and implicating pathogene-tic treatments still needs to be developed. Aim: To assess the role of cytotoxic lymphocytes in the maintaining of inflammation in COPD. Materials and methods: To examine immune status in 37 patients with COPD exacerbation or remission and 24 healthy donors (control group), blood cytotoxic T-lymphocytes and NK-cells contents were measured using indirect immunofluorescence method. Absolute and relative numbers of lymphocytes expressing CD3, CD4, CD8, CD16, CD20, CD23, CD25, CD54, CD71, CD72, HLA-DR, CD95 antigens, membrane immunoglobulins  M (mIgM) and G (mIgG) were estimated. Results: In COPD, significantly increased numbers of blood cytotoxic lymphocytes were demonstrated independently from the disease stage (p < 0.001). During COPD exacerbation, significant elevations of CD4, CD8, CD20, CD72, NК-cells numbers, serum mIgM and mIgG were demonstrated. During remission, CD20 and CD72 content returned to normal, though, increased numbers of other cytotoxic cells persisted promoting inflammation and progressive damage of pulmonary and bronchial tissues. Conclusion: Observed changes may be due to excessive stimulation of T-cell component of immune system in COPD patients both in exacerbation and remission. Relative reduction of total T-lymphocyte numbers indicates non-specific (non-infectious) inflammation type. High cytotoxic potential of immune system results in pulmonary damage and promotes development of pneumosclerosis and emphysema.

About the authors

N. A. Raspopina

I.M. Sechenov First Moscow State Medical University; 8/2 Trubetskaya ul., Moscow, 119991, Russian Federation

Author for correspondence.
MD, PhD, Professor, Internal and Occupational Diseases and Pulmonology Departmen Russian Federation

E. G. Shuganov

Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation

MD, PhD, Professor, Internal Diseases Department, Postgraduate Medical School Russian Federation

F. N. Paleev

Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation

MD, PhD, Professor, Director Russian Federation

Zh. M. Salmasi

N.I. Pirogov Russian National Research Medical University; 1 Ostrovityanova ul., Moscow, 117997, Russian Federation

MD, PhD, Professor, Department of Pathophysiology and Clinical Pathophysiology Russian Federation

A. E. Shuganov

Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation

Fellow, Internal Diseases Department, Postgraduate Medical Schoo Russian Federation


  1. Global Initiative for Chronic Obstruction Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (Updated 2011). Available from:
  2. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–52.
  3. Chapman KR, Boulet LP, Rea RM, Franssen E. Suboptimal asthma control: prevalence, detection and consequences in general practice. Eur Respir J. 2008;31(2):320–5.
  4. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925–31.
  5. Lacoma A, Prat C, Andreo F, Domínguez J. Biomarkers in the management of COPD. Eur Respir Rev. 2009;18(112):96–104.
  6. Folli C, Chiappori A, Pellegrini M, Garelli V, Riccio AM, De Ferrari L, Braido F, Canonica GW. COPD treatment: real life and experimental effects on peripheral NK cells, their receptors expression and their IFN-γ secretion. Pulm Pharmacol Ther. 2012;25(5):371–6.
  7. Hodge G, Mukaro V, Holmes M, Reynolds PN, Hodge S. Enhanced cytotoxic function of natural killer and natural killer T-like cells associated with decreased CD94 (Kp43) in the chronic obstructive pulmonary disease airway. Respirology. 2013;18(2):369–76.
  8. Порядин ГВ, Салмаси ЖМ, Зильбер ИЕ. Особенности поверхностного фенотипа лимфоцитов при ХОБЛ. В: Материалы Х Международного конгресса «Современные проблемы аллергологии, иммунологии и иммунофармакологии». Казань, 20–23 мая 2009 г. с. 304. (Poryadin GV, Salmasi ZhM, Zil’ber IE. Characteristic of surface lymphocytes phenotype in COPD. In: Proceedings of the X International Congress “Contemporary issues of allergology, immunology and immunopharmacology”. 2009 May 20–23; Kazan, Russia. p. 304. Russian).
  9. Порядин ГВ, Салмаси ЖМ, Макарков АИ. Механизмы регуляции экспрессии поверхностных структур дифференцированного лимфоцита. Иммунология. 1997;(3):4–8. (Poryadin GV, Salmasi ZhM, Makarkov AI. [Surface structures expression regulatory mechanisms in differentiated lymphocyte]. Immunologiya. 1997;(3):4–8. Russian).
  10. Фримель Г, ред. Иммунологические методы. [Перевод с нем.]. М.: Медицина; 1987. 472 с. (Friemel H, editor. Immunological working methods. Moscow: Meditsina; 1987. 472 p. Russian).
  11. Fairclough L, Urbanowicz RA, Corne J, Lamb JR. Killer cells in chronic obstructive pulmonary disease. Clin Sci (Lond). 2008;114(8):533–41.
  12. Howard LM, Reen DJ. CD72 ligation regulates defective naive newborn B cell responses. Cell Immunol. 1997;175(2):179–88.
  13. Robertson MJ, Cameron C, Lazo S, Cochran KJ, Voss SD, Ritz J. Costimulation of human natural killer cell proliferation: role of accessory cytokines and cell contact-dependent signals. Nat Immun. 1996-1997;15(5):213–26.
  14. Harnett M, Rigley K. The role of G-proteins versus protein tyrosine kinases in the regulation of lymphocyte activation. Immunol Today. 1992;13(12):482–6.

Copyright (c) 2016 Raspopina N.A., Shuganov E.G., Paleev F.N., Salmasi Z.M., Shuganov A.E.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies